Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06031415 · ClinicalTrials.gov registry record · Phase 1
Study of GS-0272 in Participants With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 20
- Study locations
NCT06031415: Active Phase 1 study of Rheumatoid Arthritis, sponsored by Gilead Sciences.
NCT06031415 is a Phase 1 study of Rheumatoid Arthritis that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 55 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06031415, a Phase 1 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA). The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GS-0272
Study Locations (20)
Other
- ARENSIA Exploratory Medicine LLC - Tbilisi
- IMSP Republican Clinical Hospital "Timofei Mosneaga", ARENSIA E.M. - Chisinau
- Chungnam National University Hospital - Daejeon
- Seoul National University Hospital - Seoul
- Ajou University Hospital - Suwon
- Cambridge Clinical Research Centre, Rheumatology Research Unit - E6, Addenbrookes Hospital - Cambridge
Texas
- Precision Comprehensive Clinical Research Solutions - Colleyville
- Accurate Clinical Research, Inc. - Houston
- Precision Comprehensive Clinical Research Solutions - Irving
- 1600 Republic Parkway - Mesquite
California
- Arizona Arthritis & Rheumatology Associates P.C. - Glendale
- Stanford School of Medicine, Division of Immunology & Rheumatology - Palo Alto
- 1238 E. Arrow Hwy - Upland
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- Jacksonville Center for Clinical Research - Jacksonville
Illinois
- Greater Chicago Specialty Physicians/ Clinical Investigation Specialists - Niles
- Greater Chicago Specialty Physicians/Clinical Investigation Specialists, Inc. - Schaumburg
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
- PA Regional Center for Arthritis and Osteoporosis Research - Wyomissing
Oregon
- Summit Headlands LLC - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT06031415 still lists
NCT06031415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06031415 names 20 study sites across 7 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06031415 about?
NCT06031415 is a clinical study titled "Study of GS-0272 in Participants With Rheumatoid Arthritis". The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA). The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS...
What is the current status of trial NCT06031415?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2023-09-28. Estimated completion is 2026-03.
What conditions does trial NCT06031415 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06031415?
The interventions under investigation include: Placebo (DRUG), GS-0272 (DRUG).
Who is sponsoring clinical trial NCT06031415?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06031415 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06031415's enrollment target sits among peer trials
55 136th of 197 higher than 61 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI